Cargando…

Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders

BACKGROUND: Although previous studies described the production of IgG antibodies in a subgroup of patients with common variable immunodeficiency (CVID) following messenger RNA vaccinations with BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (CVID responders), the functionality...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauerwein, Kai M.T., Geier, Christoph B., Stemberger, Roman F., Rossmanith, Raphael, Akyaman, Hüseyin, Illes, Peter, Fischer, Michael B., Eibl, Martha M., Walter, Jolan E., Wolf, Hermann M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Academy of Allergy, Asthma & Immunology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715258/
https://www.ncbi.nlm.nih.gov/pubmed/36463978
http://dx.doi.org/10.1016/j.jaci.2022.11.013
_version_ 1784842408133918720
author Sauerwein, Kai M.T.
Geier, Christoph B.
Stemberger, Roman F.
Rossmanith, Raphael
Akyaman, Hüseyin
Illes, Peter
Fischer, Michael B.
Eibl, Martha M.
Walter, Jolan E.
Wolf, Hermann M.
author_facet Sauerwein, Kai M.T.
Geier, Christoph B.
Stemberger, Roman F.
Rossmanith, Raphael
Akyaman, Hüseyin
Illes, Peter
Fischer, Michael B.
Eibl, Martha M.
Walter, Jolan E.
Wolf, Hermann M.
author_sort Sauerwein, Kai M.T.
collection PubMed
description BACKGROUND: Although previous studies described the production of IgG antibodies in a subgroup of patients with common variable immunodeficiency (CVID) following messenger RNA vaccinations with BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (CVID responders), the functionality of these antibodies in terms of avidity as measured by the dissociation rate constant (k(dis)) and the antibody response to booster immunization has not been studied. OBJECTIVE: We sought to analyze in CVID responders and healthy individuals, the avidity of anti–SARS-CoV-2 serum antibodies and their neutralization capacity as measured by surrogate virus–neutralizing antibodies in addition to IgG-, IgM-, and IgA-antibody levels and the response of circulating (peripheral blood) follicular T-helper cells after a third vaccination with BNT162b2 SARS-CoV-2 messenger RNA vaccine. METHODS: Binding IgG, IgA, and IgM serum levels were analyzed by ELISA in patients with CVID responding to the primary vaccination (CVID responders, n = 10) and healthy controls (n = 41). The binding avidity of anti–spike antibodies was investigated using biolayer interferometry in combination with biotin-labeled receptor-binding-domain of SARS-CoV-2 spike protein and streptavidin-labeled sensors. Antigen-specific recall T-cell responses were assessed by measuring activation-induced markers by flow cytometry. RESULTS: After the third vaccination with BNT162b2, IgG-, IgM-, and IgA-antibody levels, surrogate virus–neutralizing antibody levels, and antibody avidity were lower in CVID responders than in healthy controls. In contrast, anti–SARS-CoV-2 spike protein avidity was comparable in CVID responders and healthy individuals following primary vaccination. Follicular T-helper cell response to booster vaccination in CVID responders was significantly reduced when compared with that in healthy individuals. CONCLUSIONS: Impaired affinity maturation during booster response provides new insight into CVID pathophysiology.
format Online
Article
Text
id pubmed-9715258
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Academy of Allergy, Asthma & Immunology
record_format MEDLINE/PubMed
spelling pubmed-97152582022-12-02 Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders Sauerwein, Kai M.T. Geier, Christoph B. Stemberger, Roman F. Rossmanith, Raphael Akyaman, Hüseyin Illes, Peter Fischer, Michael B. Eibl, Martha M. Walter, Jolan E. Wolf, Hermann M. J Allergy Clin Immunol Covid-19 BACKGROUND: Although previous studies described the production of IgG antibodies in a subgroup of patients with common variable immunodeficiency (CVID) following messenger RNA vaccinations with BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (CVID responders), the functionality of these antibodies in terms of avidity as measured by the dissociation rate constant (k(dis)) and the antibody response to booster immunization has not been studied. OBJECTIVE: We sought to analyze in CVID responders and healthy individuals, the avidity of anti–SARS-CoV-2 serum antibodies and their neutralization capacity as measured by surrogate virus–neutralizing antibodies in addition to IgG-, IgM-, and IgA-antibody levels and the response of circulating (peripheral blood) follicular T-helper cells after a third vaccination with BNT162b2 SARS-CoV-2 messenger RNA vaccine. METHODS: Binding IgG, IgA, and IgM serum levels were analyzed by ELISA in patients with CVID responding to the primary vaccination (CVID responders, n = 10) and healthy controls (n = 41). The binding avidity of anti–spike antibodies was investigated using biolayer interferometry in combination with biotin-labeled receptor-binding-domain of SARS-CoV-2 spike protein and streptavidin-labeled sensors. Antigen-specific recall T-cell responses were assessed by measuring activation-induced markers by flow cytometry. RESULTS: After the third vaccination with BNT162b2, IgG-, IgM-, and IgA-antibody levels, surrogate virus–neutralizing antibody levels, and antibody avidity were lower in CVID responders than in healthy controls. In contrast, anti–SARS-CoV-2 spike protein avidity was comparable in CVID responders and healthy individuals following primary vaccination. Follicular T-helper cell response to booster vaccination in CVID responders was significantly reduced when compared with that in healthy individuals. CONCLUSIONS: Impaired affinity maturation during booster response provides new insight into CVID pathophysiology. American Academy of Allergy, Asthma & Immunology 2023-04 2022-12-02 /pmc/articles/PMC9715258/ /pubmed/36463978 http://dx.doi.org/10.1016/j.jaci.2022.11.013 Text en © 2022 American Academy of Allergy, Asthma & Immunology. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Covid-19
Sauerwein, Kai M.T.
Geier, Christoph B.
Stemberger, Roman F.
Rossmanith, Raphael
Akyaman, Hüseyin
Illes, Peter
Fischer, Michael B.
Eibl, Martha M.
Walter, Jolan E.
Wolf, Hermann M.
Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
title Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
title_full Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
title_fullStr Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
title_full_unstemmed Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
title_short Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders
title_sort functionally impaired antibody response to bnt162b2 booster vaccination in cvid igg responders
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715258/
https://www.ncbi.nlm.nih.gov/pubmed/36463978
http://dx.doi.org/10.1016/j.jaci.2022.11.013
work_keys_str_mv AT sauerweinkaimt functionallyimpairedantibodyresponsetobnt162b2boostervaccinationincvidiggresponders
AT geierchristophb functionallyimpairedantibodyresponsetobnt162b2boostervaccinationincvidiggresponders
AT stembergerromanf functionallyimpairedantibodyresponsetobnt162b2boostervaccinationincvidiggresponders
AT rossmanithraphael functionallyimpairedantibodyresponsetobnt162b2boostervaccinationincvidiggresponders
AT akyamanhuseyin functionallyimpairedantibodyresponsetobnt162b2boostervaccinationincvidiggresponders
AT illespeter functionallyimpairedantibodyresponsetobnt162b2boostervaccinationincvidiggresponders
AT fischermichaelb functionallyimpairedantibodyresponsetobnt162b2boostervaccinationincvidiggresponders
AT eiblmartham functionallyimpairedantibodyresponsetobnt162b2boostervaccinationincvidiggresponders
AT walterjolane functionallyimpairedantibodyresponsetobnt162b2boostervaccinationincvidiggresponders
AT wolfhermannm functionallyimpairedantibodyresponsetobnt162b2boostervaccinationincvidiggresponders